Starpharma (ASX:SPL) has announced that its Australian developed anti-COVID nasal spray Viraleze is now registered for use in India.
The announcement comes as the country battles the devastating impact of COVID-19 with over 29 million cases and 363,000 deaths.
Viraleze has been shown to inactivate a broad spectrum of respiratory viruses, including more than 99.9 per cent of coronavirus SARS-CoV-2 that causes COVID-19.
The company said the product can be applied either before or after exposure and can be used in high-risk or crowded environments up to four times a day.
It can also be stored at room temperature and does not require cold storage or specialised transportation.
“India continues to record hundreds of thousands of COVID-19 cases every day. Starpharma has worked extremely hard to achieve expedited registration of Viraleze given the significant need,” said Starpharma CEO Dr Jackie Fairley.
“The active in Viraleze, astodrimer sodium, has been shown to be highly active against multiple strains and variants of SARS-CoV-2, including the problematic Alpha variant, which is the second most common variant in India and has been responsible for COVID-19 cases in about 135 countries.”
Viraleze first launched in the UK at LloydsPharmacy in March and in Europe in early May.